Kaplan–Meier plots by investigator of: A, duration of response in responders (n = 61), B, duration of complete response in complete responders (n = 50), and C, duration of complete and partial responses among responders (n = 61), and D, progression-free survival in the dose-expansion cohort (n = 98; efficacy-evaluable population).
PD
DISEASE
Note: in Panel A and C, one patient had PR and PD at the same assessment and was therefore excluded from the duration of response among responders curves. CR, complete response; NE, not estimable; No., number; PD, progressive disease; PR, partial response.
